Published in Urol Oncol on January 22, 2009
Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nat Commun (2015) 1.64
Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer (2010) 1.41
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res (2009) 1.35
LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet (2010) 1.11
Familial testicular germ cell tumours. Best Pract Res Clin Endocrinol Metab (2010) 0.89
The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nat Rev Urol (2016) 0.81
Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Fam Cancer (2009) 0.80
Cyclic AMP and c-KIT signaling in familial testicular germ cell tumor predisposition. J Clin Endocrinol Metab (2013) 0.79
Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. Asian J Androl (2015) 0.78
Local signalling environments and human male infertility: what we can learn from mouse models. Expert Rev Mol Med (2010) 0.77
Understanding the agreement of histology of familial testicular tumors. Urol Oncol (2010) 0.75
Sequential bilateral testicular tumours presenting with intervals of 20 years and more. BMC Urol (2013) 0.75
Should extragonadal germ cell tumors be included in studies of families with testicular germ cell tumors? Hered Cancer Clin Pract (2013) 0.75
Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort. Cancer Epidemiol Biomarkers Prev (2015) 0.75
Close ties: an exploratory Colored Eco-Genetic Relationship Map (CEGRM) study of social connections of men in Familial Testicular Cancer (FTC) families. Hered Cancer Clin Pract (2012) 0.75
Mosaic chromosome Y loss and testicular germ cell tumor risk. J Hum Genet (2017) 0.75
Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med (2007) 4.95
Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer (2004) 2.97
Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer (2001) 2.30
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol (2003) 1.95
Clinical epidemiology of testicular germ cell tumors. World J Urol (2004) 1.92
Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update (2006) 1.87
Epidemiology of testicular cancer: an overview. Int J Cancer (2005) 1.80
Trinucleotide repeats not the only cause of anticipation. Lancet (1997) 1.70
Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncol (2005) 1.68
Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst (2005) 1.51
A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer (1997) 1.31
Genetic predisposition to testicular germ-cell tumours. Lancet Oncol (2004) 1.28
The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer (1997) 1.28
Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer (2004) 1.20
Familial testicular cancer in a single-centre population. Eur J Cancer (1999) 1.17
Familial risks in testicular cancer as aetiological clues. Int J Androl (2006) 1.13
Bilateral testicular germ cell tumors. Report of nine cases and review of the literature. Cancer (1986) 1.09
Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer (2001) 1.06
Inheritance and testicular cancer. Br J Cancer (1995) 1.00
Genetic and environmental risk factors for testicular cancer. Int J Androl (2007) 0.97
Linkage between androgen receptor gene CAG trinucleotide repeat length and testicular germ cell cancer histological type and clinical stage. Eur J Cancer (2004) 0.95
Candidate regions for testicular cancer susceptibility genes. The International Testicular Cancer Linkage Consortium. APMIS (1998) 0.94
Testis cancer. J Urol (2007) 0.93
Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS (2003) 0.92
Familial testicular cancer: report of six cases and review of the literature. Mayo Clin Proc (1990) 0.91
Risk factors for testicular cancer--differences between pure non-seminoma and mixed seminoma/non-seminoma? Int J Androl (2006) 0.90
Testicular germ cell tumours in Iceland: a nationwide clinicopathological study. APMIS (2006) 0.80
Malignant testicular germ cell tumors in a father and two sons. Case report and literature review. Cancer (1986) 0.79
Father-son testicular tumors: evidence for genetic anticipation? A case report and review of the literature. Cancer (2000) 0.79
Familial patterns of testicular cancer. Urology (1984) 0.79
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res (2007) 6.91
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Arginine methylation an emerging regulator of protein function. Mol Cell (2005) 6.49
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics (2004) 5.65
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics (2006) 5.56